The Effects of Polyphenol-rich Berry Juice on Blood Pressure in Hypertensive Subjects
Pre-hypertension, Hypertension
About this trial
This is an interventional prevention trial for Pre-hypertension
Eligibility Criteria
Inclusion Criteria:
- Pre-hypertension or hypertension systolic blood pressure in the 130-179 mmHg range and/or diastolic blood pressure in the 85-109 mmHg range)
- BMI 20-35 kg/m2
- Stable weight (change <4 kg previous 12 weeks)
Exclusion Criteria:
- Regular use of blood pressure lowering agens
- Diabetes type I or II
- Smokers
- Allergy to grape, cherries, blueberries/bilberries, black currant, aronia
- Supplements for weight loss
- Changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation, termination or changes in dosage) last 30 days prior to inclusion or during the study period (run-in and intervention)
- Participation in a drug trial during the previous 30 days
Sites / Locations
- University of Oslo
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Active Comparator
Active Comparator
Control
Mana-juice
Optijuice
12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups. Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.
12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia). Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.
12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant. Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks.